Hawaii district court upholds state 340B contract pharmacy law
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The court held that Hawaii’s law is not preempted by the federal law, does not violate the Constitution’s spending clause and does not discriminate against federal contractors. “At least at this stage, AstraZeneca has not shown a likelihood of success on — or even serious questions going to — the merits of this argument,” the court wrote in its ruling.
Related News Articles
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…
Headline
The Minnesota Court of Appeals Feb. 17 affirmed a lower court decision in ruling that the state’s 340B contract pharmacy law is not preempted by federal law.…
Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The 5th U.S. Circuit Court of Appeals Feb. 9 affirmed a district court ruling upholding Louisiana’s 340B contract pharmacy law. The state law prohibits…